Company news: K-V Pharmaceutical and Ther-Rx

Share this article:
In a blow to K-V Pharmaceutical, the FDA said it will not take action against pharmacies that make hydroxyprogesterone caproate, the active ingredient in K-V's recently approved pre-term labor prevention drug Makena. K-V had sent a letter to pharmacists indicating that the agency will no longer allow them to make or compound the injectable drug. “This is not correct,” said FDA in a statement, adding it would not pursue enforcement unless the compounded products are unsafe, of substandard quality or are not compounded according to standards. K-V's branded drug subsidiary Ther-Rx started promoting Makena in March.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs


Reimagining healthcare? We want to hear about it.
 
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters

MM&M inVISION

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.